Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC
(Singapore--January 31, 2021 2:40 p.m. SPT 1:40 a.m. EST)--Patient-reported outcomes from the phase III CROWN study showed that time to ...